Verrica Pharmaceuticals Management
Management criteria checks 3/4
Verrica Pharmaceuticals' CEO is Jayson Rieger, appointed in Nov 2024, has a tenure of 1.75 years. total yearly compensation is $741.40K, comprised of 40.5% salary and 59.5% bonuses, including company stock and options. directly owns 1.07% of the company’s shares, worth $910.99K. The average tenure of the management team and the board of directors is 1.8 years and 8.3 years respectively.
Key information
Jayson Rieger
Chief executive officer
US$741.4k
Total compensation
| CEO salary percentage | 40.46% |
| CEO tenure | 1.8yrs |
| CEO ownership | 1.1% |
| Management average tenure | 1.8yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$31m |
| Mar 31 2026 | n/a | n/a | -US$18m |
| Dec 31 2025 | US$741k | US$300k | -US$18m |
| Sep 30 2025 | n/a | n/a | -US$26m |
| Jun 30 2025 | n/a | n/a | -US$49m |
| Mar 31 2025 | n/a | n/a | -US$66m |
| Dec 31 2024 | US$1m | US$48k | -US$77m |
Compensation vs Market: Jayson's total compensation ($USD741.40K) is about average for companies of similar size in the US market ($USD650.37K).
Compensation vs Earnings: Jayson's compensation has been consistent with company performance over the past year.
CEO
Jayson Rieger (50 yo)
Dr. Jayson M. Rieger, Ph D., M.B.A., is President, CEO & Director of Verrica Pharmaceuticals Inc. from November 5, 2024. Dr. Rieger served as Non-Executive Independent Director at Lytix Biopharma AS since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$741.40k | 1.07% $ 911.0k | |
| Interim Chief Financial Officer | 1.8yrs | US$614.60k | 0.11% $ 94.2k | |
| Chief Medical Officer | 1.4yrs | US$382.36k | 0.014% $ 11.7k | |
| COO, Chief Legal Officer & Secretary | 1.7yrs | no data | 0.12% $ 104.4k | |
| Executive Vice President of Technical Operations | 6.8yrs | no data | no data | |
| Head of Drug Development | 6yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: VRCA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.7yrs | US$741.40k | 1.07% $ 911.0k | |
| Independent Director | 8.3yrs | US$79.34k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$69.34k | 0% $ 0 | |
| Director | 10.7yrs | no data | 1.09% $ 931.3k | |
| Independent Director | 1.4yrs | US$45.32k | 0.000010% $ 8.5 | |
| Chairman of the Board | 10.7yrs | no data | 26.53% $ 22.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.2yrs | US$55.59k | 0.000060% $ 51.2 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: VRCA's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/16 23:20 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verrica Pharmaceuticals Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Raghuram Selvaraju | H.C. Wainwright & Co. |